Although cachectic cytokines, such as TNF-α and IL-6, are elevated in the sera of cancer patients, clinical trials with one-target inhibitors have proven ineffective (Mantovani et al., 2013; Tsoli and Robertson, 2013). This evidence concerns the gene IL6 and cancer.